JP6499657B2 - Ｐｉ３ｋ阻害剤の組み合わせ - Google Patents

Ｐｉ３ｋ阻害剤の組み合わせ Download PDF

Info

Publication number
JP6499657B2
JP6499657B2 JP2016535650A JP2016535650A JP6499657B2 JP 6499657 B2 JP6499657 B2 JP 6499657B2 JP 2016535650 A JP2016535650 A JP 2016535650A JP 2016535650 A JP2016535650 A JP 2016535650A JP 6499657 B2 JP6499657 B2 JP 6499657B2
Authority
JP
Japan
Prior art keywords
cancer
dihydroimidazo
quinazolin
methoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016535650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501983A (ja
JP2017501983A5 (enExample
Inventor
リウ，ニーンシユウ
Original Assignee
バイエル ファーマ アクチエンゲゼルシャフト
バイエル ファーマ アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル ファーマ アクチエンゲゼルシャフト, バイエル ファーマ アクチエンゲゼルシャフト filed Critical バイエル ファーマ アクチエンゲゼルシャフト
Publication of JP2017501983A publication Critical patent/JP2017501983A/ja
Publication of JP2017501983A5 publication Critical patent/JP2017501983A5/ja
Application granted granted Critical
Publication of JP6499657B2 publication Critical patent/JP6499657B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016535650A 2013-12-03 2014-11-28 Ｐｉ３ｋ阻害剤の組み合わせ Expired - Fee Related JP6499657B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195485.1 2013-12-03
EP13195485 2013-12-03
PCT/EP2014/075886 WO2015082322A1 (en) 2013-12-03 2014-11-28 COMBINATION of PI3K-INHIBITORS

Publications (3)

Publication Number Publication Date
JP2017501983A JP2017501983A (ja) 2017-01-19
JP2017501983A5 JP2017501983A5 (enExample) 2017-12-28
JP6499657B2 true JP6499657B2 (ja) 2019-04-10

Family

ID=49683606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016535650A Expired - Fee Related JP6499657B2 (ja) 2013-12-03 2014-11-28 Ｐｉ３ｋ阻害剤の組み合わせ

Country Status (6)

Country Link
US (1) US10117874B2 (enExample)
EP (1) EP3077002B1 (enExample)
JP (1) JP6499657B2 (enExample)
CN (1) CN105934256B (enExample)
CA (1) CA2932221C (enExample)
WO (1) WO2015082322A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
WO2015082378A1 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
JP2020503365A (ja) * 2017-01-05 2020-01-30 エムビーシー ファーマ， インコーポレイテッド 骨疾患および骨関連疾患のための骨標的治療薬を使用する薬物組合せ処置
CA3068324A1 (en) * 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
EA020542B1 (ru) 2004-02-20 2014-12-30 Алгета Ас Альфа-излучающие частицы гидроксиапатита
US20070141066A1 (en) * 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
GB201007353D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201007354D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
US9675616B2 (en) 2010-11-11 2017-06-13 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines
CN103339133B (zh) 2010-11-11 2016-06-15 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
DE102011079031A1 (de) 2011-07-12 2013-01-17 Algeta Asa Flüssigkeitsbehälter

Also Published As

Publication number Publication date
JP2017501983A (ja) 2017-01-19
CA2932221A1 (en) 2015-06-11
WO2015082322A1 (en) 2015-06-11
US10117874B2 (en) 2018-11-06
EP3077002A1 (en) 2016-10-12
CA2932221C (en) 2022-02-22
CN105934256B (zh) 2019-12-27
EP3077002B1 (en) 2020-04-22
CN105934256A (zh) 2016-09-07
US20160303136A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
US10117874B2 (en) Combination of PI3K-inhibitors
US11046699B2 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
US12576084B2 (en) Methods for treating testicular and ovarian adrenal rest tumors
EA020022B1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
JP2022177113A (ja) Ｐｉ３ｋ－阻害剤の組み合わせ
WO2018153969A1 (en) Combination of atr kinase inhibitors with radium-223 salt
US10124007B2 (en) Combination of PI3K-inhibitors
WO2015082376A2 (en) Use of pi3k-inhibitors
WO2016087490A1 (en) Combination of pi3k-inhibitors
US11185549B2 (en) Combination of a PI3K-inhibitor with an androgen receptor antagonist
WO2020043617A1 (en) Combination of pi3k-inhibitors and targeted thorium conjugates
CN120813352A (zh) Dgk（二酰基甘油激酶）抑制剂的组合
HK1228733A1 (en) Combination of p13k-inhibitors
US20170226063A1 (en) Dna2 inhibitors for cancer treatment
TW201417816A (zh) Ａｋｔ抑制劑組合
HK40040045A (en) Methods for treating testicular and ovarian adrenal rest tumors
HK40040045B (en) Methods for treating testicular and ovarian adrenal rest tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190315

R150 Certificate of patent or registration of utility model

Ref document number: 6499657

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees